Literature DB >> 196739

Viral oncolysate in the management of malignant melanoma. I. Preparation of the oncolysate and measurement of immunologic responses.

W A Cassel, D R Murray, A H Torbin, Z L Olkowski, M E Moore.   

Abstract

Primary explants of human malignant melanoma were utilized in the preparation of oncolysates by Newcastle disease virus. The concentrated lysate, administered parenterally, was employed in an effort to augment antitumor immunologic responses in patients with metastatic melanoma. Observed cellular changes suggested a benefit, but humoral antibody measurements were not impressive.

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 196739     DOI： 10.1002/1097-0142(197708)40:2<672::aid-cncr2820400213>3.0.co;2-y

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


  18 in total

1.  A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate.

Authors:  W A Cassel; D R Murray
Journal:  Med Oncol Tumor Pharmacother       Date:  1992

Review 2.  Combined modality therapy of malignant melanoma.

Authors:  E M Hersh; J U Gutterman; C M McBride
Journal:  World J Surg       Date:  1979-07-30       Impact factor: 3.352

Review 3.  Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions.

Authors:  Dmitriy Zamarin; Peter Palese
Journal:  Future Microbiol       Date:  2012-03       Impact factor: 3.165

4.  Recent advances of oncolytic virus in cancer therapy.

Authors:  Moumita Mondal; Jingao Guo; Ping He; Dongming Zhou
Journal:  Hum Vaccin Immunother       Date:  2020-02-20       Impact factor: 3.452

5.  A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire.

Authors:  F M Batliwalla; B A Bateman; D Serrano; D Murray; S Macphail; V C Maino; J C Ansel; P K Gregersen; C A Armstrong
Journal:  Mol Med       Date:  1998-12       Impact factor: 6.354

6.  Adjuvant treatment of locally advanced renal cancer with autologous virus-modified tumor vaccines.

Authors:  H H Kirchner; P Anton; J Atzpodien
Journal:  World J Urol       Date:  1995       Impact factor: 4.226

7.  Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. II. Establishment of specific systemic anti-tumor immunity.

Authors:  V Schirrmacher; R Heicappell
Journal:  Clin Exp Metastasis       Date:  1987 Apr-Jun       Impact factor: 5.150

8.  Immune response of chimpanzee to purified melanoma 250 kilodalton tumor-associated antigen.

Authors:  G M Stuhlmiller; T L Darrow; D M Haupt; H F Seigler
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

9.  An overview on the development of newcastle disease virus as an anti-cancer therapy.

Authors:  Abdul Rahman Omar; Aini Ideris; Abdul Manaf Ali; Fauziah Othman; Khatijah Yusoff; Jafri Malin Abdullah; Haryati Shila Mohamad Wali; Madihah Zawawi; Narayani Meyyappan
Journal:  Malays J Med Sci       Date:  2003-01

Review 10.  Oncolytic viruses.

Authors:  J Nemunaitis
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.651
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.